Found 1,117 investors
Daniel Bragiel
United States
Mr. Rory Riggs is the Founder and serves as Chief Executive Officer at Locus. Mr. Riggs is a Co-Founder and serves as Board Member at Cibus. Mr. Riggs is also the Co-Founder and serves as a General Partner at Scientia Ventures. Mr.Riggs serves as the Chairman at eReceivables. He also is an Angel Investor. Since April 2010, Mr. Riggs has served as founder and Chief Executive Officer of Syntax Analytics, LLC, a development stage venture focused on creating a new information technology platform for large-scale portfolio management. Since June 2006, Mr. Riggs has also served as Managing Member of New Ventures, a venture fund focused on biotechnology and healthcare. Mr. Riggs has been the Managing Member of Balfour LLC, an investment management company focused on biotechnology and healthcare, since January 2001. Mr. Riggs served as the President of Biomatrix, Inc., a biomedical company, from 1996 until 2000. In addition, he was the Chief Financial Officer of Biomatrix from 1996 to 1998. He serves on the boards of directors of Royalty Pharma (Chair), Intra-Cellular Therapies, Inc., eReceivables, LLC (Chair), and GeneNews, Ltd. From 1991 to 1995, he was Chief Executive Officer of RF&P Corporation, an investment company owned by the Virginia Retirement System. He was also Managing Director of PaineWebber and Company, a stock brokerage and asset management firm, in the mergers and acquisitions field. Mr. Riggs holds a B.A. from Middlebury College, Vermont, and an M.B.A. from Columbia University.
Individual/Angel
Daniel Naor
United States
Mr. Byron Smith serves as Board Member at Preferral. He serves as Board Member at In the Bowl Animal Health. He also serves as Managing Director at Mountain Group Partners. He serves as Board Member at AngelEye Health. He served as Board Member at AgTech Accelerator. Mr. Smith currently serves on or has visitation rights to the board of directors of the following companies: NuSirt Biopharma, a company focused on developing products that combine the Company's discoveries with currently marketed and well defined pharmaceutical products that target unmet needs in our society; Silicon Ranch, a developer and operator of utility-scale solar facilities that provides turn-key renewable energy solutions to industry and utility partners; ORIG3N, a biotechnology company that collects DNA samples and researches and develops treatments for genetically inherited diseases, as well as offers a series of genetic tests that provide reports and insights on various aspects of the test-taker; AgTech Accelerator, a unique startup accelerator focused on discovering and developing emerging agricultural technology companies; Preferred, a platform designed to streamline the patient referral process; and VIDA Recovery Centers, a company that operates medication-assisted treatment clinics. Mr. Smith previously served on the board of directors of Aspire Health, a healthcare company that specializes in providing an extra layer of support to patients facing a serious illness; MedCenterDisplay, a company that installs and owns digital health networks in hospitals and other provider settings; and Myomo (NYSE:MYO), a medical device company that has developed an IP-protected custom myoelectric elbow orthotic device that enables individuals afflicted with stroke and other neuromuscular conditions to self-initiate and control movement of a partially paralyzed arm using their own muscle signals. Prior to his involvement with MGP, Mr. Smith held a long and distinguished career in the wireless and tech spaces. After receiving an MBA from the University of Chicago, Mr. Smith began his career at Procter & Gamble and PepsiCo in brand management and advertising. After eight years in packaged goods marketing, Mr. Smith transitioned into technology. First, in the early days of wireless, Mr. Smith served at Verizon (formally GTE); prior to the merger creating Verizon, all U.S. operating areas reported to him. In early 2000, Mr. Smith served as the EVP/GM and Chief Marketing Officer with Excite@Home. In Silicon Valley, Mr. Smith gained experience in media/content and internet technology/infrastructure. Mr. Smith moved home to TN in 2002 with Asurion as EVP/CMO. He led the relocation of Asurion's headquarters from Silicon Valley to Nashville. Mr. Smith was also a founding board member at The Nashville Entrepreneur Center and sits on the boards of The Trinity Forum in Washington D.C., Montgomery Bell Academy and Lost Valley Ranch in Colorado. Recently, Mr. Smith taught entrepreneurship as an adjunct professor at Vanderbilt University's Owen Graduate School of Management.
Individual/Angel
Dansk Erhvervsinvestering
Denmark
Dansk Erhvervsinvestering is a venture capital firm established in 1983 and based in Copenhagen, Denmark. The firm invests in the biotech, medical technology, service, healthcare, industrial and consumer products sectors. It has turned into a "closed-end fund" and no longer seeks any new investments.
Venture Capital
David Asper
United States
Mr. Andrew Schwab is a Co-Founder and serves as the Managing Partner of 5AM Ventures. He serves as a Board Member at Enliven Therapeutics, CAMP4 and TMRW Life Sciences. He also served as the Board Member at Precision Nanosystems. Also, he serves as Co-Chief Executive Officer & Director at 5:01 Acquisition. He served as Board Member at Cleave Therapeutics. Prior to founding 5AM Ventures in 2002, he was a Principal at Bay City Capital (BCC). After joining BCC in 1999, he led the firm's investment and merchant banking activities for such companies as Cubist Pharmaceuticals, Metabolex, PTC Therapeutics, Symyx and Syrrx. Prior to joining BCC, Mr. Schwab was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm's investments in and served on the Boards of Directors of RuiYi, Cleave Biosciences, Biodesy, DVS Sciences, Flexion Therapeutics, Ikaria, Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Panomics (acquired by Affymetrix), Synosia (Acquired by Biotie) and Viveve. He received a B.S. with Honors in Genetics & Ethics from Davidson College. He also served as Board Member at Startide Sciences. He also serves as the Board Member at Escient Pharmaceuticals.
Individual/Angel
David Endler
Switzerland
Mr. Dweep Chanana serves as Managing Partner at Anchor International Investments. He also serves as Venture Partner at Convergence Partners (Switzerland). He serves as a Board Member at Roambee. He served as Executive at Anchor International Investments. He also serves as an Angel Investor at Dweep Chanana. He is also a Venture Partner at Momenta Partners. He has over 10 years of experience advising or investing in companies across the growth cycle in Industrial IoT, financial services, energy and consumer sectors in the US, Europe, and Asia. He was previously Head of Venture Investments at Momenta Partners, where he led 7 industrial IoT investments. Previously he was Managing Director at Touchstone Ventures, a direct investment firm advising family offices on growth-stage investments, served as Director, Strategy and Business Development for Family Services at UBS Wealth Management, and led a UN-financed market entry and financing program in Kenya.
Individual/Angel
David Hochman
United States
Mr. Hochman has served as the Chairman of our Board since 2016, and as Chairman of the Board of Motus GI Medical Technologies Ltd., our wholly owned subsidiary, since 2011. Since May 2018, he has been Chairman and Chief Executive Officer of Orchestra BioMed, Inc., a biomedical innovation company focused on bringing high impact procedure based therapeutic innovations to life through risk reward sharing partnerships. From 2006 until 2019, he served as Managing Partner of Orchestra Medical Ventures, LLC, an investment firm that employed a strategy to create, build and invest in medical technology companies intended to generate substantial clinical value. Mr. Hochman has also served as President of Accelerated Technologies, Inc., a medical device accelerator company previously managed by Orchestra Medical Ventures, LLC, and now a wholly owned subsidiary of Orchestra BioMed, Inc. Mr. Hochman has over twenty-four years of medical innovation, entrepreneurial, venture capital and investment banking experience. Mr. Hochman served as a board member of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, from 2013 until 2020. He was a co-founder of Caliber Therapeutics, Inc., a wholly owned subsidiary of Orchestra BioMed, Inc., and was on the Board of Caliber Therapeutics, Inc. from 2009 until 2018. He was a co-founder of BackBeat Medical, Inc., a wholly owned subsidiary of Orchestra BioMed, Inc., and served as its President and a member of its Board since inception in 2010 until 2018. He was a co-founder of FreeHold Surgical, Inc., a wholly owned subsidiary of Orchestra BioMed, Inc., and served as a member of its Board from 2011 until 2018. He also served as a director of Adgero Biopharmaceuticals Holdings, Inc until 2020 when it was acquired by Kintara Therapeutics, Inc. (NASDAQ:KTRA). Prior to joining Orchestra Medical Ventures LLC, Mr. Hochman was Chief Executive Officer of Spencer Trask Edison Partners, LLC, an investment partnership focused on development stage healthcare companies. He was also Managing Director of Spencer Trask Ventures, Inc. during which time he led financing transactions for over twenty early-stage companies. From 1999 to 2006 Mr. Hochman was a board advisor of Health Dialog Services Corporation, a leader in collaborative healthcare management that was acquired in 2008 by the British United Provident Association. From 2005 to 2007, he was a co-founder and board member of PROLOR Biotech, Inc., a biopharmaceutical company developing longer lasting versions of approved therapeutic proteins, which was purchased by Opko Health (NYSE: OPK) in 2013. He is also President and a Board Member of the Mollie Parnis Livingston Foundation, a family foundation. He has a B.A. degree with honors from the University of Michigan. Mr. Hochman was selected as a director due to his history as a director of Motus GI Medical Technologies Ltd., our wholly owned subsidiary, his leadership experience at other public companies, including medical technology companies, his financial experience and his expertise in governance matters.
Individual/Angel
David Karnstedt
United States
Mr. Diego Ballesteros is a Co-Founder of BEWE ( Business/Productivity Software) and serves as its Chief Executive Officer and Board Member. Mr. Ballesteros is one of Spain's most prominent serial entrepreneurs and business angels and the man behind some of the most successful acquisitions in Spain and Latin America. Cabify, Woom Fertility and co-investments with Seaya Ventures form part of his investment portfolio. His first entrepreneurial experience started in 1997 with online classified ads platform Ocioteca and MundoSalud (acquired by Sanitas of Bupa Group). One of his biggest successes has been on-demand food delivery platforms, SinDelantal in Spain and SinDelantal Mexico, both acquired by Just Eat in 2012 and 2015, respectively. He is currently sole founder of Bewe SaaS for beauty and wellness professionals.
Individual/Angel
Dawson James Securities
Boca Raton, Florida, United States
Dawson James Securities is a full service investment firm specializing in healthcare, biotechnology, technology, and clean-tech sectors.
Biotechnology
CleanTech
Health Care
Venture Capital
Dechuang Investment
China
Founded in 2010, Dechuang Investment is an early and growth-stage venture capital firm based in Shanghai, China. The firm seeks to make investments in sectors like advanced materials, clean energy, biotechnology, and environmental protection industries.
Venture Capital
Deepak Gurnani
Canada
Dr. Richard Gregory serves as Board Member at ProMIS Neurosciences. In this capacity he provides leadership and direction to the Research organization and is responsible for the generation of development candidates based upon ImmunoGen's Antibody Drug Conjugate technology. Prior to ImmunoGen, Richard held a variety of roles at Genzyme and Sanofi-Genzyme, including Vice President for Gene Therapy, Head of Corporate Research and Head of R&D for the Sanofi/Genzyme R&D Center. Rich received his BSc in Biochemistry from Virginia Tech, his PhD in Biochemistry from the University of Massachusetts, and did his post-doctoral training in cancer genetics at the Worcester Foundation for Experimental Biology. He is the co-author of over 60 peer-reviewed publications and 23 issued U.S. patents in the area of biotechnology. Richard is a Fellow of the American Institute for Medical and Biological Engineering.
Individual/Angel
DeepBlue Ventures
United States
DeepBlue Ventures is a Silicon Valley-based venture capital firm that provides early stage funding. The firm seeks to invest in companies operating in the mobile technology, consumer internet and IoT sectors.
Venture Capital
DeepTech Future Fonds
Germany
DeepTech Future Fonds is an investment firm and is based in Bonn, Germany. The firm focuses on companies ranging from traditional deep-tech areas such as industry 4.0/IoT, robotics, artificial intelligence, quantum computing, blockchain, and process automation, to companies with a tech-based business model from sectors such as digital health, new energy, fintech, smart cities, and certain areas of the biotech industry.
Venture Capital
Deep Ventures (Venture Capital)
United States
Deep Ventures is a venture capital firm based in San Francisco, California. The firm prefers to invest in deep technology, aerospace, artificial intelligence, biotechnology, decentralization, hardware, and healthcare sectors.
Venture Capital
DEFT
Birmingham, Alabama, United States
Startup StudioвАЛ with rockstar Engineers + Entrepreneurs, in a world-class prototyping lab. (Focus: IoT, AI & Robotics).
Advanced Materials
Artificial Intelligence
Internet of Things
Machine Learning
Predictive Analytics
Racing
Robotics
Venture Capital
Incubator
Dendera Venture
Sweden
Founded in 1990, Dendera Venture is a venture capital investment firm based in Malmo, Sweden. The firm prefers to invest in the biotech and technology sectors.
Venture Capital
Dennis Porto
Boston, Massachusetts, United States
Dennis Porto is a seed-stage investor in tech companies leveraging frontier technology like bitcoin, AI, and IoT.
Individual/Angel
Devon Gundry
United States
Mr. Mark Li serves as the President and Chief Executive Officer at Resolution Bioscience. He is also an angel investor. Mark is an investor and serial entrepreneur. He pioneered early desktop publishing in the book, magazine and multimedia CD-ROM industry while at Ziff-Davis Publishing. He was part of the two-person startup team, which founded Yahoo! Europe and was responsible for starting and overseeing engineering for regional Yahoo!s in 23 countries and languages. Mark's father was a cardiothoracic surgeon and mother was a nurse - dinner table conversations driving home the critical need for better medical technologies and connecting them directly to patient outcomes. Mark's grandfather, Dr. Choh Hao Li, was a pioneering biochemist who first identified, purified and synthesized human growth hormone as well as identifying beta-endorphin amongst other major advancements. He is interested in applying startup methodologies from the tech industry to medical device development.
Individual/Angel
Diamond BioFund
Taipei, T'ai-pei, Taiwan
Diamond BioFund is a company that provides funds in life science sector, dedicated to biotechnology innovation.
Venture Capital
Diane Loviglio
United States
Mr. Farzad Nazem serves as Advisor at SignalFire. He serves as Board Member at Nautilus Biotechnology. He also serves as Strategic Advisor at January AI. He earned a B.S. degree in Computer Science with highest honors. He serves on the boards of NextBio and HAND Foundation.
Individual/Angel
Showing 361 to
380 of
1,117 results